

Our Ref. No. : BSE/LODR/2024/0503

Date : 24th October, 2024

To,
Corporate Relationship Department,
BSE Limited,
14th Floor, P.J. Towers,
Dalal Street, Fort,
Mumbai – 400 001

BSE Equity Scrip Code : 530665

Dear Sirs,

SUB : Outcome of Board Meeting

With reference to the above subject, we hereby submit the following outcome of the Meeting of the Board of Directors held today, 24th October, 2024 at 17:00 p.m. at the Registered Office of the Company and concluded at 17.30 p.m.:

1. The Board considered and approved unaudited Standalone Financial Statement for quarter and Six months ended 30th September, 2024 along with Limited Review Report.
2. Considered & approved disclosure of Related Party Transaction u/r 23 (9) of SEBI LODR, 2015.

Kindly acknowledge the same & oblige.

Thanking you,

For Zenith Healthcare Limited

(Mahendra Raycha)
Chairman & Managing Director

ZENITH HEALTHCARE LIMITED

CIN : L24231GJ1994PLC023574

Reg Office :- 504, Iscon Elegance, Prahlad Nagar Cross Road Nr. Anand Dham Jain Derasar, S. G. Road, Ahmedabad, Gujarat, India, 380051.

Tel No. 079-66168889, Email id :- mahendrazenith@hotmail.com

UNAUDITED FINANCIAL RESULTS FOR THE PERIOD ENDED 30TH SEPTEMBER, 2024

(Rs. In Lakhs)

SR.NO.	PARTICULARS.	Quarters Ended on			Half Year Ended on		Financial Year
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	ended on
		(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	31.03.2024 (AUDITED)
	INCOMES						
I	Revenue from Operations	302.79	257.13	349.35	559.92	751.02	1,447.17
II	Other Income	7.79	8.17	4.46	15.96	8.96	23.00
III	Total Income (I + II)	310.59	265.30	353.81	575.89	759.98	1,470.17
IV	EXPENSES.						
(a)	Cost of materials consumed	162.85	88.52	134.34	251.37	288.34	688.49
(b)	Purchase of Stock in Trade.	13.22	6.70	0.01	19.92	55.86	67.59
(c)	Changes of Inventories of Finished Goods, Work in Progress, Work in Trade.	(5.62)	9.12	29.19	3.50	60.84	83.89
(d)	Employee benefits expense	47.51	42.46	39.99	89.97	81.88	172.51
(e)	Finance Cost	0.35	0.31	0.49	0.66	0.57	1.37
(f)	Depreciation and Amortisation Expenses	4.09	4.08	5.51	8.17	10.68	20.93
(g)	Other Expenses	70.32	98.50	132.69	168.82	225.62	407.80
	TOTAL EXPENSES (IV (a to g))	292.73	249.69	342.22	542.42	723.79	1,442.59
V	Profit/(Loss) before Exceptional Items and Tax. (III-IV)	17.85	15.61	11.59	33.46	36.19	27.58
VI	Exceptional Items. & Extraordinary Item	-	-	-	-	-	-
VII	Profit/ (Loss) Before Tax. (V-VI)	17.85	15.61	11.59	33.46	36.19	27.58
VIII	TAX EXPENSES.						
(a)	Current Tax.	8.42	-	-	8.42	-	7.00
(b)	Deferred Tax.	0.09	-	-	0.09	-	0.23
	Total Tax Expenses.	8.51	-	-	8.51	-	7.23
IX	NET PROFIT / (LOSS) FOR THE PERIOD	9.34	15.61	11.59	24.95	36.19	20.35
X	Other Comprehensive Income	-	-	-	-	-	-
XI	Total Income for the year (IX-X)	9.34	15.61	11.59	24.95	36.19	20.35
XII	Paid up Equity Share Capital (Amount in lacs) Rs. 1 Face value per share)	537.39 Rs. 1/-	537.39 Rs. 1/-	537.39 Rs. 1/-	537.39 Rs. 1/-	537.39 Rs. 1/-	537.39 Rs. 1/-
XIII	Reserve excluding revaluation reserves as per balance sheet			-	-		196.39
XIV	Earning Per Share (In Rupees)						
(i)	Basic.	0.017	0.029	0.022	0.046	0.070	0.038
(ii)	Diluted.	0.017	0.029	0.022	0.046	0.070	0.038

NOTES:

- 1 These financial result were reviewed by the Board of Directors and thereafter have been approved by the board of directors at its meeting held on Thursday, Oct 24, 2024. The Statutory Auditors have carried out limited review of the financial result for the half year ended on Sept 30, 2024.
- 2 The financial statement has been prepared in accordance with Indian Accounting Standard under historical cost convention on the accrual basis except certain financial instruments which are measured at fair values, the provision of the Companies Act, 2013 ('Act') (to the extend notified) and guidelines issued by the Securities and Exchange Board of India (SEBI). The Ind AS are prescribed under section 133 of the Act read with the
- 3 Company has only one reportable segment - Pharmaceuticals Trading as per requirement of Ind AS 108.
- 4 Figures for the previous period have been regrouped/ rearranged/ reclassified wherever considered necessary to correspond with the current period's classification/group's disclosure.

For, Zenith Healthcare Limited

Mahendra C. Raycha
Managing Director
DIN : 00577647
Dated : 24th Oct 2024
Place : Ahmedabad

ZENITH HEALTHCARE LIMITED

CIN : L24231GJ1994PLC023574

Reg Office :- 504, Iscon Elegance, Prahlad Nagar Cross Road Nr. Anand Dham Jain Derasar, S. G. Road, Ahmedabad, Gujarat, India, 380051.

Tel No. 079-66168889, Email id :- mahendrazenith@hotmail.com

STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2024

(Rs. In Lakhs)

PARTICULARS.	AS AT 30 Sep 2024	AS AT 31 Mar 2024
	UNAUDITED	AUDITED
ASSETS.		
Non-current assets		
Property, plant and equipment		
- Tangible assets	167.03	139.82
- Intangible assets	0.09	0.09
- Capital Work in Progress	-	-
Financial Assets:		
- Investments	0.32	0.32
- Loans and Advances	83.35	83.41
- Others	7.36	7.36
Deferred Tax Assets	11.07	11.16
Other Non-Current Assets	-	-
Assets held for Sale and Discounted Operations	-	-
Sub-total- Non Current Assets	269.23	242.15
Current assets		
Inventories	189.25	197.67
Financial Assets:		
- Trade Receivables	289.27	227.20
- Cash and cash equivalents	55.57	77.56
- Bank Balance other than above	207.45	177.00
Loans and Advances		
Other financial current assets	-	-
Current tax assets (Net)	6.76	8.13
Other current assets	34.85	57.93
Sub-total- Current Assets	783.16	745.49
TOTAL	1,052.38	987.64
EQUITY AND LIABILITIES.		
Equity		
Equity share capital	537.39	537.39
Other Equity	221.35	196.39
Sub-total- Shareholder's funds	758.74	733.78
NON CURRENT LIABILITIES.		
Deferred Tax Liabilities.	-	-
Long Term Borrowing	-	-
Other Long term Liabilities.	-	-
Sub-total- Non Current Liabilities	-	-
CURRENT LIABILITIES.		
Short Term Borrowing	-	-
Trade payables		
- Total outstanding dues of micro and small enterprises	-	-
- Total outstanding dues of creditors other than micro and small enterprises	119.18	57.63
Other Financial Liabilities	-	-
Short Term Provisions	-	0.95
Other Current Liabilities	174.47	195.28
Sub-total-Current Liabilities	293.65	253.86
TOTAL	1,052.38	987.64

For, Zenith Healthcare Limited

Mahendra C. Raycha
Managing Director
DIN : 00577647
Dated : 24th Oct 2024
Place : Ahmedabad

ZENITH HEALTHCARE LIMITED

CIN : L24231GJ1994PLC023574

Reg Office :- 504, Iscon Elegance, Prahlad Nagar Cross Road Nr. Anand Dham Jain Derasar, S. G. Road, Ahmedabad,
Gujarat, India, 380051.

Tel No. 079-66168889, Email id :- mahendrazenith@hotmail.com

CASH FLOW STATEMENT FOR THE PERIOD ENDED 30TH SEPTEMBER, 2024**(Rs.In Lakhs)**

Particulars	For the period ended 30 Sep 2024	For the year ended 31 March 2024
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax	33.46	27.58
Depreciation and amortisation expense	8.17	20.93
Interest Expense	0.66	1.37
Operating profit before changes in Operating Assets and Liabilities	42.29	49.89
A. CHANGES IN OPERATING ASSETS AND LIABILITIES		
Increase / (Decrease) in Trade Payables	61.55	(39.64)
Increase / (Decrease) in Provisions	(0.95)	3.57
Increase / (Decrease) in Other Current Liabilities	(20.81)	74.77
(Increase) / Decrease in Inventories	8.42	128.12
(Increase) / Decrease in Trade Receivables	(62.07)	30.07
(Increase) / Decrease in Other Current Assets	23.08	(10.18)
(Increase) / Decrease in Loans and Advances	-	4.00
(Increase) / Decrease in other Non Current Assets	-	(48.83)
Exceptional Items		
Finance Cost	(0.66)	(1.37)
Income tax paid	(7.05)	(16.78)
Net cash flow generated from / (used in) operating activities (A)	43.80	173.62
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property plant & equipment	(35.38)	(10.59)
Loans given repaid	0.05	(0.01)
Investment in Fixed Deposits	(30.45)	(177.01)
Net cash flow from/(used in) investing activities (B)	(65.78)	(187.61)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Net cash flow from / (used in) financing activities (C)	-	-
Net Increase / (decrease) in cash and cash equivalents (A+B+C)	(21.98)	(13.99)
Cash and cash equivalents at the beginning of the year	77.56	91.54
Cash and cash equivalents at the end of the year	55.57	77.55

For, Zenith Healthcare Limited

Mahendra C. Raycha
Managing Director
DIN : 00577647
Dated : 24th Oct 2024
Place : Ahmedabad

Doshi Doshi & Co

Chartered Accountants

A908, 9th Floor, Venus Stratum,
West Wing, Venus Grounds,
Nehrunagar, Ahmedabad – 380015
Phone :- +91 91674 04303
Email :- chintan@ddco.in

Independent Auditor's Review Report on the Quarter and Six Months Ended September 30, 2024, Unaudited Financial Results of ZENITH HEALTHCARE LIMITED pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To

The Board of Directors

ZENITH HEALTHCARE LIMITED

504, ISCON ELEGANCE, PRAHLAD NAGAR CROSS ROAD,
NR. ANAND DHAM JAIN DERASAR, S. G. ROAD,
AHMEDABAD - 380051

1. We have reviewed the accompanying statement of unaudited financial results of **Zenith Healthcare Limited** (the 'Company') for the quarter ended September 30, 2024 and year to date from April 01, 2024 to September 30, 2024, the statement of Assets and Liabilities as on the even date and the statement of cash flow for the half year ended on that date (the "Statement"). This statement is prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.

A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results, prepared in accordance with applicable Indian Accounting Standards and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulation of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Doshi Doshi & Co,**
Chartered Accountants
Firm Registration No.: 153683W


Chintan Doshi

Partner
Membership No.:158931



Place: Ahmedabad
Date: October 24, 2024
UDIN: 24158931BKAUTA8049

General information about company

Name of The Company	ZENITH HEALTHCARE LIMITED		
BSE Scrip Code	530665		
NSE Symbol	NOTLISTED		
MSE Symbol	NOTLISTED		
Date of Start of Financial Year	01	04	2024
Date of End of Financial Year	31	03	2025
Reporting Period	First half yearly		
Date of Start of Reporting Period	01	04	2024
Date of End of Reporting Period	30	09	2024
Level of rounding to be used in disclosing related party transactions	Lakhs		
Whether the company has any related party?	Yes		
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes		

(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	No

[Home](#)[Validate](#)

Related party transactions

Sr No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty		
	Name	PAN	Name	PAN	Relationship of counterparty with the entity or its subsidiary
	Add	Delete			
1	ZENITH HEALTHCARE LIMITED	AAACZ0715E	MAHENDRA C. RAYCHA	ADLPR2810F	Managing Director
2	ZENITH HEALTHCARE LIMITED	AAACZ0715E	NEELA MAHENDRABHAI RAYCHA	ADLPR2812H	Non Executive Director
3	ZENITH HEALTHCARE LIMITED	AAACZ0715E	AKSHIT MAHENDRA RAYCHA	AKXPR5789E	Joint Managing Director
4	ZENITH HEALTHCARE LIMITED	AAACZ0715E	MIHIR SATISHBHAI SHAH	BQHPS4187C	Company Secretary
5	ZENITH HEALTHCARE LIMITED	AAACZ0715E	PRASHANT KUMAR GUPTA	BTAPG3392K	Chief Financial Officer
6	ZENITH HEALTHCARE LIMITED	AAACZ0715E	RAY REMEDIES PRIVATE LIMITED	AACCR0893F	MD is Common Director/Shareholder
7	ZENITH HEALTHCARE LIMITED	AAACZ0715E	RAXIN HEALTHCARE	AAGFR1030H	Mahendra Raycha is a shareholder of Raxin Healthcare. MD is Common Director/Shareholder
8	ZENITH HEALTHCARE LIMITED	AAACZ0715E	ZENITH MEDICINE PRIVATE LIMITED	AACCV7254L	MD is Common Director/Shareholder
9	ZENITH HEALTHCARE LIMITED	AAACZ0715E	ACHYUT HEALTHCARE LIMITED	AABCA3138P	Common Director/Shareholder
Total value of transaction during the reporting period					

						Additi
Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any fi
				Opening balance	Closing balance	Nature of indebt(issuance of debi etc.)
		NA	1200000.00	0.00	0.00	
RENT		NA	450000.00	0.00	0.00	
		NA	750000.00	0.00	0.00	
SALARY		NA	156720.00	0.00	0.00	
SALARY		NA	186186.00	0.00	0.00	
RENT PAID / SALES/PURCHASE		NA	394785.00	0.00	0.00	
SALES / PURCHASE AND JOB CHARGE		NA	654446.00	0.00	23714.00	
Reimbursement		NA	0.00	0.00	0.00	
RENT/ Reimbursement		NA	220525.00	0.00	0.00	
			4012662			



Applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details

of loans, inter-corporate deposits, advances or

Details of the loans, inter-corporate deposits, advances or investments

Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for utilised by the
------	--------	---	-------------------	--------	--------------------	-----------------------------------

